Efficacy vs Effectiveness

Efficacy refers to how well an intervention performs under controlled, ideal conditions; effectiveness refers to how well it performs in real-world, everyday practice.

The distinction is foundational to clinical research methodology. Efficacy is measured in tightly controlled settings , typically randomised controlled trials (RCTs) , where participant eligibility is narrow, adherence is closely monitored, and confounding variables are minimised. A result obtained under these conditions tells researchers what an intervention can do at its best.

Effectiveness, by contrast, is assessed in real-world populations: people with co-morbidities, variable adherence, diverse genetic backgrounds, and all the other noise that controlled trials deliberately exclude. Effectiveness studies , including pragmatic trials, cohort studies, and post-market surveillance; ask what an intervention actually does when deployed across a general population. The gap between the two measures is sometimes called the efficacy–effectiveness gap, and it is not always small.

A third related term, efficiency, adds the dimension of resource use, that is, whether the outcomes achieved are worth the costs involved. Efficiency sits within the domain of health economics and is distinct from both efficacy and effectiveness, though the three are frequently conflated in lay reporting.

In the Australian regulatory context, the Therapeutic Goods Administration (TGA) evaluates both efficacy data (from sponsor-submitted clinical trials) and, where available, real-world effectiveness data when assessing whether a therapeutic good meets the required standards for inclusion on the Australian Register of Therapeutic Goods (ARTG). Sponsors are required to present evidence under the Therapeutic Goods Act 1989 (Cth), and the TGA's evidentiary guidelines distinguish between these data types explicitly.

Sources: